What is the primary purpose of this 10-Q filing for investors?

The primary purpose of this 10-Q filing is to provide investors with a concise overview of Eli Lilly's financial performance and condition for the fiscal quarter ending August 11, 1994. It serves as an official update on the company's operations, including key financial metrics and any significant events that occurred during the period.

What specific financial details can an investor typically find in a 10-Q report like this?

A 10-Q report typically includes unaudited interim financial statements (balance sheets, income statements, and cash flow statements), management's discussion and analysis of financial condition and results of operations, and disclosures on any material changes in internal controls or significant legal proceedings. Investors should look for information on revenue growth, profitability, and cash generation.

Given this is a historical filing from 1994, what are the key considerations for analyzing it today?

When analyzing a historical filing from 1994, it's crucial to consider the broader economic and industry context of that era. Investors should research the pharmaceutical market landscape in the mid-1990s, including competitive pressures, major drug approvals or patent expiries relevant to Eli Lilly at that time, and the company's strategic initiatives from that period to understand the reported results within their historical context.

Where can I find more detailed financial information beyond what's summarized in this 10-Q?

While the 10-Q provides interim updates, investors can find more comprehensive financial data and historical trends in Eli Lilly's annual reports (10-K filings) for the relevant years, as well as in subsequent 10-Q filings. Additionally, financial data aggregators and historical SEC filing databases can offer further resources for in-depth analysis.

LLY 10-Q Quarterly Report Q3 FY1994 — Revenue, Net Income, EPS

Summary

Eli Lilly and Company (LLY) filed its 10-Q report for the period ending August 11, 1994. This filing provides a snapshot of the company's financial performance and position during the reported quarter. While specific financial figures and operational details are not fully detailed in the provided text, the filing indicates a period of active reporting and regulatory engagement for the company. Investors would typically look to this report for updates on sales, earnings, research and development progress, and any significant events that may impact the company's future outlook. As this is a historical filing from 1994, the context of the pharmaceutical industry at that time, including prevailing market conditions, competitive landscape, and regulatory environment, is crucial for a comprehensive understanding. Investors should focus on trends in key therapeutic areas, patent expirations, pipeline developments, and any mentions of new product launches or clinical trial results that were relevant in the mid-1990s. Understanding these elements is key to assessing Lilly's performance and strategic direction during this specific fiscal quarter.

Key Highlights

1Quarterly report (10-Q) filed by Eli Lilly and Company (LLY) for the period ending August 11, 1994.
2The filing date was August 11, 1994, indicating timely reporting.
3This document is a crucial regulatory filing for investors seeking financial and operational updates.
4The report covers a specific fiscal quarter, providing insights into short-term business performance.
5Information contained within a 10-Q typically includes financial statements, management discussion and analysis, and other material disclosures relevant to investors.
6Investors would analyze this report to assess the company's revenue, profitability, and cash flow trends.
7Contextual understanding of the 1994 pharmaceutical market is necessary for full analysis.

ELI LILLY & Co Quarterly Report for Q3 Ended Aug 12, 1994

Summary

Key Highlights

Frequently Asked Questions